2025年2月27日，施能康公司（Synerk）宣布，公司自主研发的靶向血管紧张素原（AGT）的寡核苷酸（siRNA）候选药物SNK-2726已获得美国食品药品监督管理局（FDA）临床试验申请（IND）批准。

December 27, 2024 - Hangzhou Sino-US Huadong Medicine Co., Ltd. (hereinafter referred to as "Huadong Medicine"), a wholly-owned subsidiary of Huadong Medicine Co., Ltd. (SZ.000963), and SynerK PharmaTech (Suzhou) Co., Ltd. (hereinafter referred to as "SynerK") have reached a strategic cooperation. The two parties will jointly develop the small nucleic acid (siRNA) drug SNK-2726, targeting angiotensinogen (AGT) for the treatment of hypertension.

化学修饰与递送系统创新已成为了目前小核酸企业亟待突破的瓶颈及未来的技术发展方向

国内siRNA新药完成首例受试者给药！施能康达成关键里程碑

siRNA-targeted therapy is an emerging therapeutic field after small molecules and antibodies, an outstanding advantage of RNA-targeted therapy is that the identification of drug candidates only needs to determine the target area related to the disease process in RNA, and for any target gene, the corresponding small nucleic acid can be designed to regulate its expression, so RNA therapy has great application potential in traditional undruggable diseases or targets, bringing revolutionary breakthr